[Phase II study of 3 new nitrosoureas, 1 American (chlorozotocin) and 2 French (RFCNU and RPCNU)].

Abstract

The results of three phase II clinical trials with three new analogues belonging to the family of nitrosoureas are reported. One of the studied agents, chlorozotocine (CZT) is American, while the other two, RFCNU and RPCNU, are French. All three drugs have a sugar radical. CZT proved effective mainly in a few cases of leukemia and in one case of blastic transformation of chronic myelocytic leukemia. RFCNU was shown to be effective in 8% of digestive tumors, in 1 out of 7 pancreatic cancers and in 3 out of 10 hepatic and pulmonary metastases from an undiscovered primary adenocarcinoma. As for RPCNU, it's action resembles that of RFCNU: tumor regression lasting for over three years was obtained in a patient with hepatic metastases from a digestive carcinoma; in another patient a regression rate exceeding 50% was seen in pulmonary metastases from a rectal tumor. One of the significant results of our study is the apparent tissular specificity of responses according to the agent given: CZT is more often efficient on the lymphatic localizations of the studied tumors (4/5 responses); RFCNU and RPCNU often proved active on hepatic metastases (17% responses). Digestive tolerance was excellent with CZT and RFCNU and not quite as satisfactory for RPCNU. As predicted by our experimental study, platelet toxicity is both less common and less severe with RFCNU than with CZT and RPCNU.

• Authors: G Mathé, P S Schein, F De Vassal, B Serrou, J L Imbach
• Journal: La semaine des hopitaux : organe fonde par l'Association d'enseignement medical des hopitaux de Paris (Sem Hop) Vol. 58 Issue 33 Pg. 1867-71 (Sep 16 1982) France
• Vernacular Title: Etude phase II des trois nouvelles nitrosourées, une américaine: la chlorozotocine et deux françaises: le RFCNU et le RPCNU.
• PMID: 6293062 (Publication Type: English Abstract, Journal Article)

Chemical References

• Antineoplastic Agents
• Nitrosourea Compounds
• chlorozotocin
• ICIG 1163
• RFCNU
• Streptozocin

Topics

• Antineoplastic Agents (adverse effects, therapeutic use)
• Drug Evaluation
• Humans
• Nitrosourea Compounds (adverse effects, therapeutic use)
• Streptozocin (adverse effects, analogs & derivatives, therapeutic use)